GENEWIZ to Highlight FuzeSeq™ Antibody, Cancer Panels at the American Association for Cancer Research Annual Meeting

South Plainfield, NJ -- April 15, 2015 -- Leading global genomics company, GENEWIZ, is proud to feature its proprietary next generation sequencing solution, FuzeSeq™ Antibody, among other genomics services and solutions, at the American Association for Cancer Research (AACR) Annual Meeting next week in Philadelphia, PA. 

FuzeSeq™ Antibody is a new next generation sequencing solution that optimizes antibody selection from diverse phage display libraries for cancer drug discovery research. Developed to improve the quality and quantity of next generation sequencing data obtained during screening of in vitro antibody selection libraries, FuzeSeq™ Antibody re-engineers the in vitro selection vectors by pairing the antibody VH and VL regions. Sequencing the full length of the paired VH-VL regions, FuzeSeq™ not only delivers a comprehensive overview of the diversity of the naïve or enriched antibody pools, but also streamlines researchers’ antibody discovery workflow. 

In addition, GENEWIZ will highlight cancer research solutions, including proprietary OncoGxOne™ Discovery cancer panels and hot spot cancer panels. OncoGxOne™ Discovery cancer panels provide comprehensive analysis for cancer research and biomarker discovery, with the ability to detect all types of genomic variations, including point mutations, indels, gene fusions, and copy number variations (CNVs). Available for nineteen major cancer types, OncoGxOne™ Discovery cancer panels detect low-frequency variations and gene fusions in both exons and introns, facilitating advancements in cancer mechanism studies as well as improved patient stratification for clinical trials. For studies requiring screening of multiple cancer genes in one assay, hot spot cancer panels provide a targeted solution for the discovery of rare somatic mutations. 

To learn more about these and other genomic solutions that streamline and optimize cancer research, visit GENEWIZ at booth 2150 at AACR. 

GENEWIZ is a global contract research organization (CRO) specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory-compliant services. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions. 

Headquartered in South Plainfield, NJ, GENEWIZ is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; Langen, Germany; and Tokyo, Japan.